Relapse after HSCT 2021 | AML risk stratification
Mark Levis
• 30 Sep 2021
Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, comments on the current European LeukemiaNet (ELN) classification of acute myeloid leukemia (AML). ELN has divided patients with AML into favourable, intermediate and poor categories relating to their prognosis, based on common mutations found in AML. Dr Levis argues that such broad groups are not informative in the case of AML because of the heterogeneity of the disease. Finally, Dr Levis comments on an ongoing study evaluating the outcomes of patients with mutations in both CBF and FLT3. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
